Quetiapine
Product Images NDC 10135-659

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Quetiapine (NDC 10135-659). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula For Quetiapine Extended-release Tablets Are An Atypical Antipsychotic Belonging To A Chemical Class, The Dibenzothiazepine Derivatives. The Chemical Designation Is 2-[2-(4-dibenzo [b,f ] [1,4] Thiazepin-11-yl- 1-piperazinyl)ethoxy]-ethanol Fumarate (2:1) (salt). It Is Present In Tablets As The Fumarate Salt. All Doses And Tablet Strengths Are Expressed As Milligrams Of Base, Not As Fumarate Salt. Its Molecular Formula Is C42h50n6o4s2•c4h4o4 And It Has A Molecular Weight Of 883.11 (fumarate Salt). (Quetiapine Extended Release 01)

Chemical structure diagram showing the molecular formula of the active ingredient in Quetiapine Extended Release by Marlex Pharmaceuticals Inc.*

FDA Label Image

Figure 1 Kaplan-meier Curves Of Time To Schizophrenic Relapse (study 3) (Quetiapine Extended Release 02)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (months) between two groups: PLA (placebo) and QTP XR (Quetiapine Extended Release). The y-axis shows the proportion of patients with relapse as a percentage, while the x-axis represents time in months.*

FDA Label Image

Figure 2 Kaplan-meier Curves Of Time To Recurrence Of A Mood Event (study 9) (Quetiapine Extended Release 03)

A line graph depicting the proportion of patients with relapse over time in weeks. The graph compares two treatment groups labeled as GTP+LIVAL and PLA+LIVAL, showing relapse proportions on the vertical axis and time duration up to 100 weeks on the horizontal axis.*

FDA Label Image

Figure 3 Kaplan-meier Curves Of Time To Recurrence Of A Mood Event (study 10) (Quetiapine Extended Release 04)

A line graph showing the proportion of patients with relapse over time in weeks, comparing two groups labeled GTP-LIVAL and PLA-LIVAL. The y-axis represents the proportion of patients with relapse as a percentage, and the x-axis represents time in weeks. The graph shows relapse rates increasing over time for both groups, with the PLA-LIVAL group having a higher relapse proportion throughout the timeline.*

FDA Label Image

Principal Display Panelndc 10135-0656-60quetiapine Extended-release Tablets, Usp150 mg Once Daily60 Tabletsrx Only (Quetiapine Extended Release 05)

Quetiapine Extended Release Tablets USP 150 mg Once Daily by Marlex Pharmaceuticals Inc. The label shows a package containing 60 tablets, with a note specifying 172.7 mg of quetiapine fumarate equivalent to 150 mg quetiapine per tablet. The label advises swallowing the tablet whole and provides storage instructions, urging to keep medication out of children's reach. The NDC is 10135-0656-60.*

FDA Label Image

Principal Display Panelndc 10135-0657-60quetiapine Extended-release Tablets, Usp200 mg Once Daily60 Tabletsrx Only (Quetiapine Extended Release 06)

Drug facts and label information for Quetiapine Extended-Release Tablets USP 200 mg once daily by Marlex Pharmaceuticals, Inc. Details include quetiapine fumarate strength, swallowing instructions, storage conditions, a warning to keep out of reach of children, and manufacturer information with barcode included.*

FDA Label Image

Principal Display Panelndc 10135-0658-60quetiapine Extended-release Tablets, Usp300 mg Once Daily60 Tabletsrx Only (Quetiapine Extended Release 07)

Label for Quetiapine Extended Release Tablets, USP, 300 mg once daily, manufactured by Marlex Pharmaceuticals Inc. The label shows the quantity as 60 tablets and includes storage instructions, dosage form, and a barcode. The label also features the Marlex Pharmaceuticals logo and states Rx Only.*

FDA Label Image

Principal Display Panelndc 10135-0659-60quetiapine Extended-release Tablets, Usp400 mg Once Daily60 Tabletsrx Only (Quetiapine Extended Release 08)

Label for Quetiapine Extended Release Tablets USP 400 mg once daily by Marlex Pharmaceuticals, Inc. The label states each tablet contains 460.5 mg quetiapine fumarate equivalent to 400 mg quetiapine. The package contains 60 tablets. Directions include swallowing whole without splitting or crushing. Storage instructions and a barcode are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.